About Arrowhead Research CorporationArrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate ™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead's pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic diseases, and ARC-HIF2 for renal cell carcinoma. For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm. Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Arrowhead Research Corporation's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Research Corporation. Source: Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will present at the following upcoming conferences. Partnerships in Drug Delivery - Boston, October 5-6, 2015 October 6, 2:45 p.m. EDT - David Rozema, Ph.D., vice president, chemistry will participate in a panel discussion titled, " Can RNA-based therapeutics really deliver?" 2015 International Meeting on Molecular Biology of Hepatitis B - Dolce Bad Nauheim, Germany, October 4-8, 2015 October 7, 5:00-7:00 p.m. CET - Christine Wooddell, Ph.D., group leader will deliver a poster presentation titled, " Integrated HBV DNA significantly contributes to serum HBsAg levels in chronically infected chimpanzees" 11 th Annual Meeting of the Oligonucleotide Therapeutics Society - Leiden, the Netherlands, October 11-14, 2015 October 14, 3:30 p.m. CET - Bruce Given, M.D., chief operating officer will deliver an oral presentation titled, " Development of RNAi-based therapeutics using DPC™ technology" The Liver Meeting 2015 ® , 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - San Francisco, November 13-17, 2015 November 15, 3:15 p.m. PST - Christine Wooddell, Ph.D., group leader will deliver an oral presentation titled, " Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg" November 17, 8:00 a.m. - 12:00 p.m. PST - Christine Wooddell, Ph.D., group leader will deliver a poster presentation titled, " Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens" A copy of presentation materials, if available, can be accessed by visiting the Events section of the company's website at http://ir.arrowheadresearch.com/events.cfm after the presentations conclude. About ARC-520 Arrowhead's RNAi-based candidate ARC-520 is being investigated in the treatment of chronic HBV infection. The small interfering RNAs (siRNAs) in ARC-520 intervene at the mRNA level, upstream of the reverse transcription process where current standard of care nucleotide and nucleoside analogues act. Arrowhead is investigating ARC-520 specifically, to determine if it can be used to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. Arrowhead has completed a Phase 1 single ascending dose study in normal volunteers and the company is conducting single dose Phase 2a studies and multiple dose Phase 2b studies in chronic HBV patients. Approximately 350-400 million people worldwide are chronically infected with the hepatitis B virus, which can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally.